Mylan is committed to supporting educational initiatives that facilitate health care provider education, advance the quality of patient care, and align with Mylan therapeutic and clinical interests.  Mylan will accept educational grant requests for the following professional medical education programs:

  • Accredited continuing medical education providers 
  • Hospitals, community health centers
  • Academic medical centers, medical universities
  • Professional medical associations/societies
  • Managed care organizations
  • Medical education partner companies/providers
Mylan is accepting applications for professional medical education programs through our online application system for the United States on Monday, February 17th - Wednesday, September 30th, 2020.

Mylan is currently accepting U.S. medical education grants for the following areas: COPD, Biosimilars, Cystic Fibrosis, and HIV/ARV.

Components of a Complete U.S. Grant Request Include - Letter of request/program description, agenda, program objectives, detailed budget, and (ACCME certificate for accredited programs).

For specific grant program priority topics for the United States, please see below.

United States 2020 Unrestricted Educational Grants Priority Topics

COPD 

  • Nebulization therapy in COPD, including in acute care settings
  • Nebulization therapy in COPD, including in Long-Term-Care settings
  • Identification of at-risk populations who might benefit from nebulized therapy (screening algorithm)
  • Variables that play a role in re-hospitalization and readmission (i.e. PIFR, devices mistakes, etc.)
  • Combination treatment strategy in COPD 
  • Ability to improve compliance with once-daily nebulized therapy
  • COPD treatment strategy for discharge after AECOPD to reduce re-hospitalization and 30-day readmission rates
  • Nebulized LAMA in LTC COPD population (exacerbations, rescue med use, ER visits)
  • Maintenance LAMA in different ethnic populations
  • Maintenance LAMA vs short acting QID evaluating efficacy and cost/time savings
  • Annual Respiratory conferences: scientific programs and educational symposia
Biosimilars 

  • Pharmacoeconomic impact of biosimilars
  • Real-world evidence on biosimilars
Cystic Fibrosis

  • Antibiotic use on CF
  • CF updates in existing and future treatments and the impact in antibiotic therapy
  • Antibiotic combination and new schemes of treatment
  • Resistance risk in patients with CF
  • Pseudomona aeruginosa eradication
HIV/ARV

  • FDCs with reduced doses in HIV treatment
  • Role of new once daily combinations based on older compounds
  • Current and evolving HIV treatment strategy based on low cost therapies
  • Budget Impact and economic repercussions of new and low cost ARVs